Jane Anderson

发表

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

T. Hassanein, K. Kowdley, D. Bernstein, 2013, The Lancet.

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

M. Washington, S. Lim, M. Shiffman, 2006, Archives of internal medicine.

M1908 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102)

Roger Williams, J. George, S. Gordon, 2008 .

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Huy Trinh, Robert Flisiak, Franck Rousseau, 2008, The New England journal of medicine.

Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.

F. Chan, N. Leung, L. Corey, 2005, Journal of hepatology.

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

Huy Trinh, Robert Flisiak, Franck Rousseau, 2011, Gastroenterology.

Antiviral response and resistance surveillance for HBeAgnegative patients enrolled in a combination study evaluatingemtricitabine plus clevudine versus emtricitabine monotherapyfor the treatment of chronic hepatitis B infection.

S. Lim, K. Borroto-Esoda, F. Rousseau, 2005 .

Impact of Early Viral Kinetics on T-Cell Reactivity during Antiviral Therapy in Chronic Hepatitis B

A. Perelson, S. Lewin, E. Shudo, 2007, Antiviral therapy.

28 EMTRICITABINE/TENOFOVIR DF COMBINATION +/− HBIG POST-ORTHOTOPIC LIVER TRANSPLANTATION TO PREVENT HEPATITIS B RECURRENCE IN PATIENTS WITH NORMAL TO MODERATE RENAL IMPAIRMENT: INTERIM RESULTS

S. Pungpapong, T. Schiano, L. Teperman, 2010 .

THREE YEARS OF TENOFOVIR DISOPROXIL (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG plus ) WITH CHRONIC HEPATITIS B (STUDY 103), PRELIMINARY ANALYSIS

M. Manns, P. Marcellin, M. Shiffman, 2009 .